Form 4: Akebia Therapeutics Director Cynthia Smith Receives Stock Options and Restricted Stock Units

Director Cynthia Smith received 30,000 restricted stock units and options to purchase 45,000 shares of Akebia Therapeutics common stock on June 6, 2024.

Summary

• On June 6, 2024, Cynthia Smith, a director of Akebia Therapeutics, Inc., was granted 30,000 restricted stock units (RSUs) and options to purchase 45,000 shares of common stock.
• The RSUs and stock options were granted under the company's 2023 Stock Incentive Plan and the Third Amended and Restated Non-Employee Director Compensation Program.
• The RSUs will vest in full on the first anniversary of the grant date or immediately prior to the first annual meeting of the company's stockholders occurring after the grant date, subject to continued service.
• The stock options, with an exercise price of $1.07, will also vest and become exercisable in full on the first anniversary of the grant date or immediately prior to the first annual meeting of the company's stockholders occurring after the grant date, subject to continued service.
• Following the transaction, Ms. Smith directly owns 125,233 shares of Akebia Therapeutics common stock and options to purchase 45,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of equity grants to a director, which is a standard practice. There are no explicit positive or negative implications for the company's performance.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued service and alignment with shareholder interests.

Industry Context

Equity grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders. The terms of the grants, such as vesting schedules, are typically designed to retain talent and reward long-term value creation.

Comparison to Industry Standards

• Equity compensation for board members is standard practice across the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options and RSUs to compensate and incentivize their directors.
• The vesting schedules and grant sizes are generally comparable to industry norms, aligning director compensation with long-term company performance.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates